Darzalex 欧盟 - 克罗地亚文 - EMA (European Medicines Agency)

darzalex

janssen-cilag international n.v. - daratumumab - multipli mijelom - monoclonal antibodies and antibody drug conjugates, antineoplastic agents - multiple myelomadarzalex is indicated: in combination with lenalidomide and dexamethasone or with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. u kombinaciji s бортезомибом, талидомидом i дексаметазоном za liječenje odraslih bolesnika s prvi put utvrđenom multiplog mijeloma, koji imaju pravo za obavljanje autologna transplantacija matičnih stanica . u kombinaciji s леналидомидом i дексаметазоном i бортезомибом i дексаметазоном za liječenje odraslih bolesnika s multiplog mijeloma, koji je dobio barem jedne prethodne terapije. in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or after the last therapy (see section 5. u monoterapiji za liječenje odraslih bolesnika s ponavljajućom i uporan multiplog mijeloma, čija je ranije terapija je uključivala inhibitor протеасом i иммуномодулирующего agent i koji je pokazao napredovanje bolesti na zadnje terapije. al amyloidosisdarzalex is indicated in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of adult patients with newly diagnosed systemic light chain (al) amyloidosis.

DARZALEX 1800mg Rastvor za injekciju 黑山共和国 - 克罗地亚文 - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

darzalex 1800mg rastvor za injekciju

druŠtvo za trgovinu na veliko farmaceutskim proizvodima "glosarij" d.o.o.-podgorica - daratumumab - rastvor za injekciju - 1800mg

DARZALEX 20mg/ml Koncentrat za rastvor za infuziju 黑山共和国 - 克罗地亚文 - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

darzalex 20mg/ml koncentrat za rastvor za infuziju

druŠtvo sa ograniČenom odgovornoŠĆu "inpharm co" podgorica - daratumumab - koncentrat za rastvor za infuziju - 20mg/ml

DARZALEX 20mg/ml Koncentrat za rastvor za infuziju 黑山共和国 - 克罗地亚文 - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

darzalex 20mg/ml koncentrat za rastvor za infuziju

druŠtvo sa ograniČenom odgovornoŠĆu "inpharm co" podgorica - daratumumab - koncentrat za rastvor za infuziju - 20mg/ml

Kyprolis 欧盟 - 克罗地亚文 - EMA (European Medicines Agency)

kyprolis

amgen europe b.v. - carfilzomib - multipli mijelom - antineoplastična sredstva - kyprolis in combination with daratumumab and dexamethasone, with lenalidomide and dexamethasone, or with dexamethasone alone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

Pepaxti 欧盟 - 克罗地亚文 - EMA (European Medicines Agency)

pepaxti

oncopeptides ab - melphalan flufenamide hydrochloride - multipli mijelom - antineoplastična sredstva - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.